jansucko / iStockphoto.com
2 November 2017Americas
Valeant pays $13m in royalty settlement
Canada-based Valeant has agreed to pay $13 million to biotechnology company PDL BioPharma to settle a dispute over royalties.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
2 September 2016 Neos Therapeutics has filed a patent infringement suit against Teva, and its subsidiary Actavis, for allegedly infringing a number of its patents.
Americas
13 May 2014 Canadian pharmaceutical company Valeant announced yesterday (May 12) that it had settled all litigation related to its acne treatment Acanya (clindamycin phosphate and benzoyl peroxide) with Actavis.
Editor's picks
Editor's picks
Americas
2 September 2016 Neos Therapeutics has filed a patent infringement suit against Teva, and its subsidiary Actavis, for allegedly infringing a number of its patents.
Americas
13 May 2014 Canadian pharmaceutical company Valeant announced yesterday (May 12) that it had settled all litigation related to its acne treatment Acanya (clindamycin phosphate and benzoyl peroxide) with Actavis.
Americas
2 September 2016 Neos Therapeutics has filed a patent infringement suit against Teva, and its subsidiary Actavis, for allegedly infringing a number of its patents.
Americas
13 May 2014 Canadian pharmaceutical company Valeant announced yesterday (May 12) that it had settled all litigation related to its acne treatment Acanya (clindamycin phosphate and benzoyl peroxide) with Actavis.